Vidya Limaye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vidya Limaye has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Grace Scott
Hanson Institute, Institute of Medical and Veterinary Science
3 shared publicationsPeter Blumbergs
Tissue Pathology, South Australia Pathology, Adelaide, South Australia, Australia
3 shared publications- Peter John Roberts-Thomson
Flinders Medical Centre
3 shared publications David Gillis
Royal Adelaide Hospital
2 shared publicationsPravin Hissaria
Immunology Department; Royal Adelaide Hospital; Adelaide South Australia Australia
2 shared publications- Adam Maundrell
Rheumatology Department, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, 5000, Australia
1 shared publication
Latest Publications
- 11 January 2017
- Published by Wiley in Internal Medicine Journal
- Vol. 47 (1) , 112-115
Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients
In South Australia, between 2000 and 2014, 57 patients with idiopathic inflammatory myositis (IIM) were treated with intravenous immunoglobulin (IVIg). We reviewed disease characteristics to determine predictors of response to therapy and IVIg dosing and duration to identify opportunities to rationalise IVIg use. Patients with dermatomyositis/polymyositis had a response rate of 77% and were more likely than inclusion body myositis to respond to therapy. Consideration should be given to the use of the lowest possible dose of IVIg and to the undertaking of trials of cessation of IVIg in patients with stable IIM.
- 11 January 2017
- Published by Wiley in Internal Medicine Journal
- Vol. 47 (1) , 112-115
Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients
In South Australia, between 2000 and 2014, 57 patients with idiopathic inflammatory myositis (IIM) were treated with intravenous immunoglobulin (IVIg). We reviewed disease characteristics to determine predictors of response to therapy and IVIg dosing and duration to identify opportunities to rationalise IVIg use. Patients with dermatomyositis/polymyositis had a response rate of 77% and were more likely than inclusion body myositis to respond to therapy. Consideration should be given to the use of the lowest possible dose of IVIg and to the undertaking of trials of cessation of IVIg in patients with stable IIM.
- 16 June 2016
- Published by Wiley in Muscle & Nerve
- Vol. 55 (2) , 270-273
ThePTPN22gene is associated with idiopathic inflammatory myopathy
Introduction The aim of this study was to determine whether a single‐nucleotide polymorphism (SNP; 1858CT, R620W) in the protein tyrosine phosphatase N22 (PTPN22) gene confers susceptibility to idiopathic inflammatory myopathy (IIM) in South Australian patients with IIM. Methods: Genotyping was performed on stored DNA from 199 patients with histologically confirmed polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM), and then compared with 455 matched controls. Associations with the 8.1 ancestral haplotype (AH), and myositis‐specific (MSA) and myositis‐associated (MAA) autoantibodies were investigated. Results: The PTPN22 R620W minor allele frequency was increased in IIM patients (50 of 398, 12.6%) compared with controls (75 of 910, 8.2%) (odds ratio 1.6, 95% confidence interval 1.1–2.3, P = 0.016). In IIM patients, there was no association between the R620W minor allele and detection of any MSA/MAA (P = 0.70), nor any evidence of epistasis with the 8.1 AH (P = 0.69). Conclusions: The PTPN22 R620W minor allele is associated with susceptibility to IIM in SA patients, independent of the 8.1 AH. Muscle Nerve, 2016 Muscle Nerve 55: 270–273, 2017
- 16 June 2016
- Published by Wiley in Muscle & Nerve
- Vol. 55 (2) , 270-273
ThePTPN22gene is associated with idiopathic inflammatory myopathy
Introduction The aim of this study was to determine whether a single‐nucleotide polymorphism (SNP; 1858CT, R620W) in the protein tyrosine phosphatase N22 (PTPN22) gene confers susceptibility to idiopathic inflammatory myopathy (IIM) in South Australian patients with IIM. Methods: Genotyping was performed on stored DNA from 199 patients with histologically confirmed polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM), and then compared with 455 matched controls. Associations with the 8.1 ancestral haplotype (AH), and myositis‐specific (MSA) and myositis‐associated (MAA) autoantibodies were investigated. Results: The PTPN22 R620W minor allele frequency was increased in IIM patients (50 of 398, 12.6%) compared with controls (75 of 910, 8.2%) (odds ratio 1.6, 95% confidence interval 1.1–2.3, P = 0.016). In IIM patients, there was no association between the R620W minor allele and detection of any MSA/MAA (P = 0.70), nor any evidence of epistasis with the 8.1 AH (P = 0.69). Conclusions: The PTPN22 R620W minor allele is associated with susceptibility to IIM in SA patients, independent of the 8.1 AH. Muscle Nerve, 2016 Muscle Nerve 55: 270–273, 2017
- 1 January 2012
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 6 (1) , 111-115
PULSED INTRAVENOUS CYCLOPHOSPHAMIDE FOR SLE RETINAL VASCULITIS
Purpose: To report a case of systemic lupus erythematosus vaso-occlusive retinopathy with severe visual loss treated with intravenous pulsed cyclophosphamide. Methods: Retrospective interventional case report. Results: A 20-year-old Cambodian woman with newly diagnosed systemic lupus erythematosus presented with acute visual loss. Fluorescein fundus angiography demonstrated occlusive retinal vasculitis. Treatment with pulsed intravenous cyclophosphamide, intravenous methylprednisolone, and anticoagulation resulted in recovery of vision from count fingers to 6/6 in both eyes. Conclusion: Early aggressive immunosuppression and anticoagulation for systemic lupus erythematosus retinal vasculitis can be beneficial in preventing disease progression and restoring vision. Further studies are needed to compare dosage regimens.
- 1 January 2012
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 6 (1) , 111-115
PULSED INTRAVENOUS CYCLOPHOSPHAMIDE FOR SLE RETINAL VASCULITIS
Purpose: To report a case of systemic lupus erythematosus vaso-occlusive retinopathy with severe visual loss treated with intravenous pulsed cyclophosphamide. Methods: Retrospective interventional case report. Results: A 20-year-old Cambodian woman with newly diagnosed systemic lupus erythematosus presented with acute visual loss. Fluorescein fundus angiography demonstrated occlusive retinal vasculitis. Treatment with pulsed intravenous cyclophosphamide, intravenous methylprednisolone, and anticoagulation resulted in recovery of vision from count fingers to 6/6 in both eyes. Conclusion: Early aggressive immunosuppression and anticoagulation for systemic lupus erythematosus retinal vasculitis can be beneficial in preventing disease progression and restoring vision. Further studies are needed to compare dosage regimens.
- 11 October 2007
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (4) , 521-523
Anti-Ro52 antibodies, antisynthetase antibodies, and antisynthetase syndrome
We present a case of antisynthetase syndrome manifesting with interstitial lung disease, mechanic’s hands, nailfold abnormalities, and subclinical myositis, in the presence of antibodies to the aminoacyl tRNA synthetase PL-12 and also to Ro52. Antibodies to Ro52 have been recently associated with idiopathic inflammatory myositis, but there have only been occasional reports of this antibody occurring in association with aminoacyl tRNA synthetases, including PL-12. Our case adds to the descriptions of the concurrence of antibodies to PL-12 and Ro52. The mechanism for the coupling of antibody response remains elusive but is likely to play a fundamental role in disease pathogenesis.
- 11 October 2007
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (4) , 521-523
Anti-Ro52 antibodies, antisynthetase antibodies, and antisynthetase syndrome
We present a case of antisynthetase syndrome manifesting with interstitial lung disease, mechanic’s hands, nailfold abnormalities, and subclinical myositis, in the presence of antibodies to the aminoacyl tRNA synthetase PL-12 and also to Ro52. Antibodies to Ro52 have been recently associated with idiopathic inflammatory myositis, but there have only been occasional reports of this antibody occurring in association with aminoacyl tRNA synthetases, including PL-12. Our case adds to the descriptions of the concurrence of antibodies to PL-12 and Ro52. The mechanism for the coupling of antibody response remains elusive but is likely to play a fundamental role in disease pathogenesis.
- 1 September 2007
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 10 (3) , 248-252
Granulomatous disease in selective IgA deficiency
- 1 September 2007
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 10 (3) , 248-252
Granulomatous disease in selective IgA deficiency
- 15 May 2007
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 10 (2) , 94-100
The epidemiology of dermatomyositis in South Australia
- 15 May 2007
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 10 (2) , 94-100
The epidemiology of dermatomyositis in South Australia
- 15 May 2007
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 10 (2) , 86-93
The clinical features of dermatomyositis in a South Australian population
- 15 May 2007
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 10 (2) , 86-93
The clinical features of dermatomyositis in a South Australian population
- 1 September 2006
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 9 (3) , 290-293
Intravenous pamidronate in the treatment of sternoclavicular hyperostosis
The SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) is a rare clinical entity in which osteosclerosis and osteolysis are consistent radiological findings. We present a patient with SAPHO syndrome manifesting as painful sternoclavicular hyperostosis treated successfully with pamidronate. For the first time, a reduction in isotope bone scan activity was documented in parallel to a favourable clinical response. Bisphosphonates have potent antiosteoclastic and anti‐inflammatory effects. By virtue of their dual effects on bone remodelling and inflammation, they seem an appropriate therapy in the management of SAPHO syndrome. This case demonstrates the efficacy of pamidronate, both clinically and radiologically, as first line therapy for patients with isolated hyperostosis.
- 1 September 2006
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 9 (3) , 290-293
Intravenous pamidronate in the treatment of sternoclavicular hyperostosis
The SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) is a rare clinical entity in which osteosclerosis and osteolysis are consistent radiological findings. We present a patient with SAPHO syndrome manifesting as painful sternoclavicular hyperostosis treated successfully with pamidronate. For the first time, a reduction in isotope bone scan activity was documented in parallel to a favourable clinical response. Bisphosphonates have potent antiosteoclastic and anti‐inflammatory effects. By virtue of their dual effects on bone remodelling and inflammation, they seem an appropriate therapy in the management of SAPHO syndrome. This case demonstrates the efficacy of pamidronate, both clinically and radiologically, as first line therapy for patients with isolated hyperostosis.